Literature DB >> 18251691

Oral adenoviral-based vaccines: historical perspective and future opportunity.

Sean N Tucker1, Debora W Tingley, Ciaran D Scallan.   

Abstract

Adenoviral vaccines delivered orally have been used for decades to prevent respiratory illness, but are now being seriously explored again as a platform technology to make vaccines against a variety of pathogens. Years of use in military populations as a preventative measure for adenoviral infection have demonstrated the safety of oral administration of adenovirus. The advantages of using this approach as a platform technology for vaccines include rapid development and distribution, as well as ease of administration. Recent discoveries may allow this platform approach to reach the clinic within a few years.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251691     DOI: 10.1586/14760584.7.1.25

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  20 in total

1.  IKKβ-induced inflammation impacts the kinetics but not the magnitude of the immune response to a viral vector.

Authors:  Emily L Hopewell; Crystina C Bronk; Michael Massengill; Robert W Engelman; Amer A Beg
Journal:  Eur J Immunol       Date:  2012-01-13       Impact factor: 5.532

2.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

3.  An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models.

Authors:  Ciaran D Scallan; Debora W Tingley; Jonathan D Lindbloom; James S Toomey; Sean N Tucker
Journal:  Clin Vaccine Immunol       Date:  2012-11-14

Review 4.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

Review 5.  Ebola virus disease candidate vaccines under evaluation in clinical trials.

Authors:  Karen A Martins; Peter B Jahrling; Sina Bavari; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2016-05-27       Impact factor: 5.217

Review 6.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

7.  Oral inoculation of chickens with a candidate fowl adenovirus 9 vector.

Authors:  Li Deng; Shayan Sharif; Eva Nagy
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

8.  Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract.

Authors:  Emeline Goffin; Justine Javaux; Eric Destexhe; Carla D Pretto; Katherine R Spindler; Bénédicte Machiels; Laurent Gillet
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

Review 9.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

Review 10.  Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

Authors:  De-chu C Tang; Jianfeng Zhang; Haroldo Toro; Zhongkai Shi; Kent R Van Kampen
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.